New Targeted Treatments for Non-small-cell Lung Cancer - Role of Nivolumab

Overview

Journal Biologics

Date 2016 Aug 19

PMID 27536062

Citations 18

Authors

Giulia Zago

Mirte Muller

Michel van den Heuvel

Paul Baas

Affiliations

Soon will be listed here.

Abstract

Non-small-cell lung cancer (NSCLC) is often diagnosed at an advanced stage of disease, where it is no longer amenable to curative treatment. During the last decades, the survival has only improved significantly for lung cancer patients who have tumors harboring a driver mutation. Therefore, there is a clear unmet need for effective therapies for patients with no mutation. Immunotherapy has emerged as an effective treatment for different cancer types. Nivolumab, a monoclonal inhibitory antibody against PD-1 receptor, can prolong survival of NSCLC patients, with a manageable toxicity profile. In two Phase III trials, nivolumab was compared to docetaxel in patients with, respectively, squamous (CheckMate 017) and non-squamous NSCLC (CheckMate 057). In both trials, nivolumab significantly reduced the risk of death compared to docetaxel (41% and 27% lower risk of death for squamous and non-squamous NSCLC, respectively). Therefore, nivolumab has been approved in the US and in Europe as second-line treatment for advanced NSCLC. Unfortunately, accurate predictive factors for patient selection are lacking, making it difficult to decide who will benefit and who will not. Currently, there are many ongoing trials that evaluate the efficacy of nivolumab in different settings and in combination with other agents. This paper reviews the present literature about the role of nivolumab in the treatment of NSCLC. Particular attention has been given to efficacy studies, toxicity profile, and current and emerging predictive factors.

Citing Articles

Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).

Abulizi A, Yan G, Xu Q, Muhetaer R, Wu S, Abudukelimu K Sci Rep. 2024; 14(1):25919.

PMID: 39472591 PMC: 11522629. DOI: 10.1038/s41598-024-75099-5.

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).

Griesinger F, Sebastian M, Brueckl W, Hummel H, Jaeschke B, Kern J JTO Clin Res Rep. 2024; 5(4):100626.

PMID: 38586301 PMC: 10995980. DOI: 10.1016/j.jtocrr.2023.100626.

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.

Rui M, Wang Y, Li Y, Fei Z BioDrugs. 2023; 38(1):157-170.

PMID: 37792142 DOI: 10.1007/s40259-023-00628-z.

Elucidation of the anti-lung cancer mechanism of Juan-Liu-San-Jie prescription based on network pharmacology and experimental validation.

Wang Y, Pan Y, Luo Y, Wu J, Fang Z, Teng W Heliyon. 2023; 9(8):e18298.

PMID: 37560652 PMC: 10407049. DOI: 10.1016/j.heliyon.2023.e18298.

Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.

Cho Y, Kim Y, Chamseddine I, Lee W, Kim H, Lee I Radiother Oncol. 2022; 168:1-7.

PMID: 35033601 PMC: 9036741. DOI: 10.1016/j.radonc.2022.01.007.

References

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

Shaw A, Kim D, Mehra R, Tan D, Felip E, Chow L . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13):1189-97. PMC: 4079055. DOI: 10.1056/NEJMoa1311107. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M . Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005; 65(3):1089-96. View

Sequist L, Soria J, Goldman J, Wakelee H, Gadgeel S, Varga A . Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1700-9. DOI: 10.1056/NEJMoa1413654. View

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

10.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

11.

Grada A, Weinbrecht K . Next-generation sequencing: methodology and application. J Invest Dermatol. 2013; 133(8):e11. DOI: 10.1038/jid.2013.248. View

12.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P . Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013; 3(6):630-5. PMC: 4160032. DOI: 10.1158/2159-8290.CD-13-0035. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Govindan R, Ding L, Griffith M, Subramanian J, Dees N, Kanchi K . Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-34. PMC: 3656590. DOI: 10.1016/j.cell.2012.08.024. View

15.

Mazieres J, Peters S, Lepage B, Cortot A, Barlesi F, Beau-Faller M . Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31(16):1997-2003. DOI: 10.1200/JCO.2012.45.6095. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Lee W, Jiang Z, Liu J, Haverty P, Guan Y, Stinson J . The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465(7297):473-7. DOI: 10.1038/nature09004. View

18.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

19.

Reynders K, Illidge T, Siva S, Chang J, De Ruysscher D . The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015; 41(6):503-10. PMC: 4816218. DOI: 10.1016/j.ctrv.2015.03.011. View

20.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View